Merck Splashes $208 Million on Abceutics for a Boost in Growth!-To The Moon - Tiger Brokers Online Investing Community - To The Moon

101
1
Favorite

Merck Splashes $208 Million on Abceutics for a Boost in Growth!

Value_investing
04-16

图片

Pharmaceutical giant $Merck(MRK)$ has acquired startup Abceutics for $208 million, acquiring the company's medical technology payloads in combination with selective enhancers (PBSEs) that have high potential in the field of antibody-drug conjugate(ADC).

ADC drugs are currently a hot area of oncology drug development, and many large pharmaceutical companies want to get a piece of the pie, and Merck is no exception.

Merck has six ADC drugs in late-stage clinical trials for cancers including small cell lung cancer, non-small cell lung cancer (NSCLC) and endometrial cancer. Mordor Intelligence predicts the global ADC drug market will grow from $12 billion this year to $44 billion in 2029.

In the last 12 months, Merck's revenue was just over $60 billion. If the company's ADC drug development is successful and gains good market share, the company's future growth potential will be greatly boosted.

Abceutics' PBSE technology binds and neutralizes free payloads, reducing their impact on healthy cells. Used with ADCs, it can slash their toxic side effects, making ADC therapy more selective and effective.

Now with PBSE in their arsenal, Merck's ADC drug research is like a tiger with wings! Side effects could be way lower than other pharma companies' drugs, giving Merck a competitive edge.

In the coming years, Merck will roll out even more ADC drugs, and acquiring Abceutics could be a huge boost for their growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

101

Report

Comment（1）

Top
Latest

JimmyTurner
·04-16
$Merck$ grabbing Abceutics for $208 million, that's like a big move lah!
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":295962658967560,"tweetId":"295962658967560","gmtCreate":1713267101430,"gmtModify":1713271083647,"author":{"id":3527667626267411,"authorId":3527667626267411,"authorIdStr":"3527667626267411","name":"Value_investing","avatar":"https://community-static.tradeup.com/news/89ffffc59ff9ac9cb9cb74f596418d44","vip":2,"userType":2,"introduction":"Stock and Earning Analysis","boolIsFan":false,"boolIsHead":false,"crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/f6a827c3620c89ae88b508b1b5ac19b9","width":"1080","height":"675"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/f6a827c3620c89ae88b508b1b5ac19b9","width":"1080","height":"675"}],"title":"Merck Splashes $208 Million on Abceutics for a Boost in Growth!","html":"<html><head></head><body><p class=\"t-img-caption\"><img alt=\"图片\" title=\"图片\" src=\"https://community-static.tradeup.com/news/f6a827c3620c89ae88b508b1b5ac19b9\" tg-width=\"1080\" tg-height=\"675\"><span>图片</span></p><p>Pharmaceutical giant <a data-mention-id=\"MRK\" class=\"teditor-mention\" data-mention-name=\"Merck\" href=\"https://ttm.financial/S/MRK\">$Merck(MRK)$</a> has acquired startup Abceutics for $208 million, acquiring the company's medical technology payloads in combination with selective enhancers (PBSEs) that have high potential in the field of antibody-drug conjugate(ADC).</p><p>ADC drugs are currently a hot area of oncology drug development, and many large pharmaceutical companies want to get a piece of the pie, and Merck is no exception.</p><p>Merck has six ADC drugs in late-stage clinical trials for cancers including small cell lung cancer, non-small cell lung cancer (NSCLC) and endometrial cancer. Mordor Intelligence predicts the global ADC drug market will grow from $12 billion this year to $44 billion in 2029.</p><p>In the last 12 months, Merck's revenue was just over $60 billion. <strong>If the company's ADC drug development is successful and gains good market share, the company's future growth potential will be greatly boosted.</strong></p><p>Abceutics' PBSE technology binds and neutralizes free payloads, reducing their impact on healthy cells. Used with ADCs, it can slash their toxic side effects, making ADC therapy more selective and effective.</p><p>Now with PBSE in their arsenal, Merck's ADC drug research is like a tiger with wings! Side effects could be way lower than other pharma companies' drugs, giving Merck a competitive edge.</p><p>In the coming years, Merck will roll out even more ADC drugs, and <strong>acquiring Abceutics could be a huge boost for their growth</strong>.  </p><p></p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img alt=\"图片\" title=\"图片\" src=\"https://community-static.tradeup.com/news/f6a827c3620c89ae88b508b1b5ac19b9\" tg-width=\"1080\" tg-height=\"675\"><span>图片</span></p><p>Pharmaceutical giant <a data-mention-id=\"MRK\" class=\"teditor-mention\" data-mention-name=\"Merck\" href=\"https://ttm.financial/S/MRK\">$Merck(MRK)$</a> has acquired startup Abceutics for $208 million, acquiring the company's medical technology payloads in combination with selective enhancers (PBSEs) that have high potential in the field of antibody-drug conjugate(ADC).</p><p>ADC drugs are currently a hot area of oncology drug development, and many large pharmaceutical companies want to get a piece of the pie, and Merck is no exception.</p><p>Merck has six ADC drugs in late-stage clinical trials for cancers including small cell lung cancer, non-small cell lung cancer (NSCLC) and endometrial cancer. Mordor Intelligence predicts the global ADC drug market will grow from $12 billion this year to $44 billion in 2029.</p><p>In the last 12 months, Merck's revenue was just over $60 billion. <strong>If the company's ADC drug development is successful and gains good market share, the company's future growth potential will be greatly boosted.</strong></p><p>Abceutics' PBSE technology binds and neutralizes free payloads, reducing their impact on healthy cells. Used with ADCs, it can slash their toxic side effects, making ADC therapy more selective and effective.</p><p>Now with PBSE in their arsenal, Merck's ADC drug research is like a tiger with wings! Side effects could be way lower than other pharma companies' drugs, giving Merck a competitive edge.</p><p>In the coming years, Merck will roll out even more ADC drugs, and <strong>acquiring Abceutics could be a huge boost for their growth</strong>.  </p><p></p></body></html>","text":"图片 Pharmaceutical giant $Merck(MRK)$ has acquired startup Abceutics for $208 million, acquiring the company's medical technology payloads in combination with selective enhancers (PBSEs) that have high potential in the field of antibody-drug conjugate(ADC). ADC drugs are currently a hot area of oncology drug development, and many large pharmaceutical companies want to get a piece of the pie, and Merck is no exception. Merck has six ADC drugs in late-stage clinical trials for cancers including small cell lung cancer, non-small cell lung cancer (NSCLC) and endometrial cancer. Mordor Intelligence predicts the global ADC drug market will grow from $12 billion this year to $44 billion in 2029. In the last 12 months, Merck's revenue was just over $60 billion. If the company's ADC drug development is successful and gains good market share, the company's future growth potential will be greatly boosted. Abceutics' PBSE technology binds and neutralizes free payloads, reducing their impact on healthy cells. Used with ADCs, it can slash their toxic side effects, making ADC therapy more selective and effective. Now with PBSE in their arsenal, Merck's ADC drug research is like a tiger with wings! Side effects could be way lower than other pharma companies' drugs, giving Merck a competitive edge. In the coming years, Merck will roll out even more ADC drugs, and acquiring Abceutics could be a huge boost for their growth.","highlighted":1,"essential":2,"paper":2,"likeSize":101,"commentSize":1,"repostSize":13,"favoriteSize":0,"link":"https://ttm.financial/post/295962658967560","repostId":0,"isVote":1,"tweetType":1,"viewCount":414,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MRK"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1204,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":295901416116432,"gmtCreate":1713271512712,"gmtModify":1713349751334,"authorId":9000000000000136,"author":{"id":9000000000000136,"authorId":9000000000000136,"name":"JimmyTurner","avatar":"https://static.tigerbbs.com/e32612860d02f31ae6eb923f14c61b63","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":295962658967560,"type":1,"supId":0,"prevId":0,"content":"$Merck$ grabbing Abceutics for $208 million, that's like a big move lah!","text":"$Merck$ grabbing Abceutics for $208 million, that's like a big move lah!","html":"$Merck$ grabbing Abceutics for $208 million, that's like a big move lah!","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}